Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers

Pathology and Oncology Research

Volumn 13, Issue 4, 2007, Pages 365-369

  Xin, Bing ^a   Yokoyama, Yoshihito ^a   Shigeto, Tatsuhiko ^a   Mizunuma, Hideki ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Meloxicam; Non specific COX inhibitor; Non steroidal anti inflammatory drugs; Ovarian cancer; Selective COX 2 inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; AUTOPSY; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MOUSE; NONHUMAN; OVARY CANCER; STOMACH PERFORATION; SURVIVAL RATE; TUMOR GROWTH;

EID: 39649098020     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02940318     Document Type: Article

References (39)

1. Aas AT, Tonnessen TI, Brun A, Salford LG: Growth inhibition of rat glioma cells in vitro and in vivo by aspirin. J Neurooncol 24: 171-180, 1995.
2. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al: Aspirin and epithelial ovarian cancer. Prev Med 33: 682-687, 2001.
3. Baron JA, Sandlers RS: Non-steroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 51: 511-523, 2000.
4. Blanco FJ, Guitian R, Moreno J, et al: Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol 26: 1366-1373, 1999.
5. Cramer DW, Harlow BL, Titus-Ernstoff L, et al: Over-the-counter analgesics and risk of ovarian cancer. Lancet 351: 104-107, 1998.
6. Craven PA, DeRubertis FR: Effect of aspirin on 1,2-dimethyl-hydrazine-induced colonic carcinogenesis. Carcinogenesis 13: 541-546, 1992.
7. Denkert C, Kobel M, Pest S, et al: Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160: 893-903, 2002.
8. di Palma A, Matarese G, Leone V, et al: Aspirin reduces the outcome of anticancer therapy in Meth A-bearing mice through activation of AKT-glycogen synthase kinase signaling. Mol Cancer Ther 5: 1318-1324, 2006.
9. Din FV, Dunlop MG, Stark LA: Evidence for colorectal cancer cell specificity of aspirin effects on NFB signalling and apoptosis. Br J Cancer 91: 381-388, 2004.
10. Drake JG, Becker JL: Aspirin-induced inhibition of ovarian tumor cell growth. J Obstet Gynecol 100: 677-682, 2002.
11. Duperron C, Castonguay A: Chemoprevention efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18: 1001-1006, 1997.
12. Ferrandina G, Lauriola L, Zannoni GF, et al: Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13: 1205-1211, 2002.
13. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics. Ca Cancer J Clin 50: 7-33, 2000.
14. Goldman AP, Williams CS, Sheng H, et al: Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 19: 2195-2199, 1998.
15. Henry D, Lim LLY, Rodriguez LS, et al: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 312: 1563-1566, 1996.
16. Kern MA, Schoneweis MM, Sahli D, et al: Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implant in nude mice. Carcinogenesis 25: 1193-1199, 2004.
17. Laudanno OM, Cesolari JA: In vivo selectivity of nonsteroidal anti-inflammatory drugs and gastrointestinal ulcer in rats. Dig Dis Sci 45: 1359-1365, 2000.
18. Li H, Kramer P, Steele V, et al: Effect of duration of treatment with piroxicam on azoxymethane-induced colon cancer, aberrant crypt foci, apoptosis and cell proliferation in rats. Cancer Lett 147: 187-19323, 1998.
19. Liu CH, Chang SH, Narko K, et al: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569, 2000.
20. Mohammed SI, Bennett PF, Craig BA, et at: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 62: 356-358, 2002.
21. Moysich KB, Mettlin C, Piver MS, et al: Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidem Biomarkers Prev 10: 903-906, 2001.
22. Piazza GA, Alberts DS, Hixson LJ, et al: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis inn rats without reduced prostaglandin levels. Cancer Res 57: 2909-2915, 1997.
23. Pollard M, Luckert PH: Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res 49: 6471-6473, 1989.
24. Prescott SM, White RL: Intimate connection between APC and prostaglandin H synthase-2. Cell 87: 783-786, 1996.
25. Reddy BS, Rao CV, Rivenson A, Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497, 1993.
26. Ricchi P, Pignata S, Di Popolo A, et al: Effect of aspirin treatment on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. Int J Cancer 73: 880-884, 1997.
27. Rozic JG, Chakraborty C, Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93: 497-506, 2001.
28. Sakamoto A, Yokoyama Y, Umemoto M, et al: Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor g in epithelial ovarian tumours. Br J Cancer 91: 633-638, 2004.
29. Sheng H, Shao J, Kirkland SC, et al: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99: 2254-2259, 1997.
30. Shibata MA, Hirose M, Masuda A, et al: Modification of BHA forestomach carcinogenesis in rats: inhibition by diethylmaleate or indomethacin and enhancement by a retinoid. Carcinogenesis 14: 1265-1269, 1993.
31. Shigemasa K, Tian X, Gu L, et al: Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 22: 99-105, 2003.
32. Smalley W, DuBois RN: Colorectal cancer and non steroidal anti-inflammatory drugs. Adv Pharmacol 39: 1-20, 1997.
33. Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2. J Biol Chem 271: 33157-33160, 1996.
34. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J Natl Cancer Inst 90: 1529-1536, 1998.
35. Tsubouchi Y, Sano H, Kawahito Y, et al: Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 20: 2867-2872, 2000.
36. Tsujii M, Kawano S, Tsuji S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
37. van Rees BP, Saukkonen K, Ristimaki A, et al: Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 196: 171-179, 2002.
38. Yao M, Kargman S, Lam EC, et al: Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63: 586-592, 2003.
39. Yokoyama Y, Sakamoto T, Sato S, Saito Y: Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol 20: 361-366, 1999.